accelerated drug discovery
Quick facts about 123INC
Global partner network
scientific and global resources network tailored specifically to the needs of early programs
Broad therapeutic focus
high value therapeutic areas, from immunology to oncology, from CNS to infectious diseases
Supported by Artificial Intelligence
our platform is AI-enabled and supported by computer aided drug design
At the forefront of disruptive science
global scientific partner network allows us to capitalize on expanding biotech modalities
Our Portfolio
-
![]()
Lomond Therapeutics brings proprietary small molecule products to <br> the clinic targeting cancer.
-
![]()
Eil Therapeutics is developing a robust pipeline of innovative treatments in the field of oncology.
-
![]()
Trawsfynydd Therapeutics is currently engaged in the development of a broad range of cancer treatments.
-
![]()
Ness Therapeutics is currently working on a number of innovative treatments in the field of oncology.
-
![]()
Celyn Therapeutics <br> is focused on advancing a pipeline of breakthrough therapeutics <br> for cancer.
-
![]()
Padarn Therapeutics <br> is developing a pipeline of oncology treatments for a wide variety <br> of cancers.
-
![]()
Vyrnwy Therapeutics <br> is currently engaged in innovative early <br>oncology drug discovery programs.
-
![]()
Ogwen Therapeutics is focused on developing breakthrough therapeutics for treatment of cancer.
-
![]()
Llydaw Therapeutics is focused on advancing a robust pipeline of innovative therapeutics for treatment of cancer.
-
![]()
Tegid Therapeutics is working on advancing breakthrough small molecules for treatment of cancer.
-
![]()
Mwyngil Therapeutics is advancing a robust pipeline in the areas of oncology and immunology.
-
![]()
Bala Therapeutics is developing breakthrough small molecules for treatment of a wide range of cancers.
-
![]()
Gwynant Therapeutics<br> is bringing proprietary small molecule products to the clinic targeting cancer.
123 INC: 3 Step Process
Design
utilizing interactive AI-enabled drug design tools, 4D modeling and direct access to Big Data
2. Fund
leveraging our expertise & our network of financial partners to select and fund programs with the highest potential
3. Execute
assisting with establishing commercialization using our global scientific partner network
Unique Tools + Direct Ties to Big Data + Accurate AI
How we are building the next-generation life science companies capable of delivering outstanding returns to our investors.
-
Models of Mutants and Variants Drug Selectivity
4D and Hybrid ML-models
Integration with proprietary chemistry environment
-
Prepared Thousands of Models for DD -targets and Properties
Giga Search in Billions of Compounds
-
RIDE: 3D and pharmacophoric search through 50B compounds
Interactive Drug Design in 3D Off-target and Properties
-
![]()
Nikolay Savchuk
ADVISOR
-
![]()
Rouslan Michtchenko
VENTURE PARTNER
-
![]()
Ronald Demuth
ADVISOR
-
![]()
Eddie Rodriguez
GENERAL COUNSEL
-
![]()
Thomas Gasser
ADVISOR
-
![]()
Pierluigi Nicotera
ADVISOR
-
![]()
Augustine Lawlor
ADVISOR
-
![]()
Valery Fokin
ADVISOR
-
![]()
John Byrd
ADVISOR
-
![]()
Simon Bennett
VENTURE PARTNER
-
![]()
Eugenio Fava
ADVISOR
-
![]()
Andrew Orry
CADD LEAD
-
![]()
Jenny Remeeva
BIOLOGY OPERATIONS
-
![]()
Jacqueline Bergseid
BIOLOGY OPERATIONS
-
![]()
Ivan Savchuk
ANALYST
-
![]()
Alexander Khvat
DISCOVERY LEAD
-
![]()
Alexei Pushechnikov
DISCOVERY LEAD
-
![]()
Volodymyr Kysil
CHEMISTRY LEAD
-
![]()
Alexey Rjakhovskiy
BIOLOGY LEAD
-
![]()
Ruben Karapetyan
PHARMACOLOGY LEAD
Our Financial Partners
Get in touch.
Interested in joining the accelerator? Reach out and we will get back to you shortly.